Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Anifrolumab by AstraZeneca for Systemic Sclerosis (Scleroderma): Likelihood of Approval
Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase...
Anifrolumab by AstraZeneca for Vitiligo: Likelihood of Approval
Anifrolumab is under clinical development by AstraZeneca and currently in Phase II for Vitiligo. According to GlobalData, Phase II drugs...
Anifrolumab by AstraZeneca for Subacute Cutaneous Lupus Erythematosus (SCLE): Likelihood of Approval
Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Subacute Cutaneous Lupus Erythematosus (SCLE). According to...
Anifrolumab by AstraZeneca for Dermatomyositis: Likelihood of Approval
Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Dermatomyositis. According to GlobalData, Phase III drugs...
Anifrolumab by AstraZeneca for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE): Likelihood of Approval
Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid...
Anifrolumab by AstraZeneca for Polymyositis: Likelihood of Approval
Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Polymyositis. According to GlobalData, Phase III drugs...
Anifrolumab by AstraZeneca for Hidradenitis Suppurativa: Likelihood of Approval
Anifrolumab is under clinical development by AstraZeneca and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase II...
Anifrolumab by AstraZeneca for Vitiligo: Likelihood of Approval
Anifrolumab is under clinical development by AstraZeneca and currently in Phase II for Vitiligo. According to GlobalData, Phase II drugs...